Clinical trial
Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chain…
NCT00298766 · Millennium Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00298766 |
|---|---|
| Title | Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chain (AL)-Amyloidosis |
| Official title | An Open-Label Phase 1/2 Study of VELCADE for Injection in Subjects With Light-Chain (AL)-Amyloidosis |
| Lead sponsor | Millennium Pharmaceuticals, Inc., Industry |
| Collaborators | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Amyloidosis |
| Intervention type | Drug |
| Interventions | VELCADE |
| Enrollment | 70 |
| Start date | Jun 1, 2005 |
| Primary completion | Jul 1, 2009 |
| Completion | Sep 1, 2009 |
| First posted | Mar 3, 2006 |
| Last update posted | Jun 25, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: